Corrigendum to “Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients” [J Crit Care 43 (2018) 202–206]

Abstract Purpose We designed this study to examine the clinical effects of polymyxin B hemoperfusion (PMX-HP) in septic shock patients. Material and methods We retrospectively examined the effects of PMX-HP in septic shock patients with intra-abdominal or gram-negative bacterial infection during October 2013–May 2016. A one-to-one matching between the PMX-HP and conventional groups was performed, and 28-day mortality, and change in inotropic score, Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic Health Evaluation II (APACHE II) score at 24 h in the two groups were compared. In addition, multivariable regression analysis and Cox proportional hazards regression model were applied in all eligible patients. Results Sixty-nine patients were eligible, of whom forty-eight patients were enrolled for matched cohort analysis. In matched cohort analysis, median change in inotropic score after 24 h (−23 [−33-−13] vs. −12 [−19-0], p = 0.007) differed significantly between the PMX-HP and conventional groups. Multivariable regression analysis revealed that PMX-HP was associated with lower 28-day mortality (odds ratio 0.18, 95% CI 0.04–0.92, p  = 0.039) and greater improvement in inotropic and APACHE II scores. Conclusions PMX-HP may have potential benefits for hemodynamic and prognostic outcomes in septic shock patients with intra-abdominal or gram-negative bacterial infection.